2019 Fall Clinical Lipid Update: Top 10 Takeaways

Step 1
Register
Step 2
Pre-Test
Step 3
Video
Step 4
Post Test
Step 5
Evaluation
Step 6
Certificate
OBJECTIVES & ACCREDITATION

Activity Title: 2019 Fall Clinical Lipid Update: Top 10 Takeaways

PROGRAM OVERVIEW
During this activity, Dr. Nihar Desai and Dr. Alan Brown discuss their top 10 takeaway messages from the National Lipid Association’s 2019 Fall Clinical Lipid Update. Tune in to learn more about the use of coronary calcium scoring and advances in lipid laboratory measurements.

ACTIVITY TYPE
Internet Enduring Activity

TARGET AUDIENCE
This activity is designed to meet the needs of lipidologists, internists, endocrinologists, registered nurses, nurse practitioners, advance practice registered nurses and those with an interest in lipid management.

LEARNING OBJECTIVES
At the Conclusion of this activity, participants should be able to:

  • Discuss the clinical recommendations for the use of coronary calcium scoring.
  • Discuss the use of lipid testing for the management of dyslipidemia and ASCVD risk.

CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s participation in the activity and post-assessment with a score of 50% or greater and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. The deadline to claim credit is May 8, 2020.

COMMERCIAL SUPPORT
This activity is supported by educational funding provided by Aegerion Pharmaceuticals, Inc. and Amarin Pharma Inc.

CREDIT DESIGNATION
CME credit provided by the National Lipid Association

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this internet enduring activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.

Nursing
The maximum number of hours awarded for this CE activity is 1.0 contact hours.

This continuing education activity offered 0.8 pharmacotherapy contact hours.

FACULTY
Alan S. Brown, MD, FNLA
Director, Division of Cardiology
Advocate Heart Institute
Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Chicago, IL
Nihar R. Desai, MD, MPH Assistant Professor of Medicine (Cardiology)
Yale School of Medicine
Haven, CT

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.

DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

PERMISSIONS
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

FACULTY/PLANNER FINANCIAL DISCLOSURES
Name Relationship Company
Brown, Alan Consultant
Speaker
Amarin, Amgen, The Medicines Company, Regeneron, Sanofi
Amarin, Amgen, Regeneron, Sanofi
Desai, Nihar Consultant Amgen, Boehringer Ingelheim, Cytokinetics, Novartis, Relypsa
STAFF / REVIEWER DISCLOSURES
Name Relationship Company
NLA N/A NLA staff has nothing to disclose.
Elkins, Casey, DNP N/A Nothing to disclose.

Publish Date: 
Thursday, May 7, 2020 - 10:15

This page was last updated: May 07, 2020